Trial Profile
Phase I /II and Pharmacological Clinical Study of Combination Chemotherapy with Irinotecan (CPT-11) and Erlotinib (Tarceva) for Recurrent Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 13 May 2016
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Irinotecan (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 23 Nov 2012 New trial record